CLOs on the Move

Amplyx Pharmaceuticals

www.amplyx.com

 
Amplyx Pharmaceuticals, Inc. is a preclinical stage company focusing on the development of small molecule drugs with enhanced efficacy and lower toxicity. Amplyx employs a platform approach to improve small molecule drugs by the addition of a second small molecule to an existing drug. The resulting, new therapeutic creates a more targeted molecule with the goal of improving treatment outcomes and improving compliance with treatment regimens. Our initial development areas are in oncology and infectious disease.
  • Number of Employees: 0-25
  • Annual Revenue: $10-50 Million
  • www.amplyx.com
  • 3210 Merryfield Row
    San Diego, CA USA 92121-1126
  • Phone: 415.578.3263

Executives

Name Title Contact Details

Similar Companies

NeuroBo Pharmaceuticals

NeuroBo Pharmaceuticals is addressing unmet needs in patients with diabetic neuropathy and Alzheimer’s disease.

Fievet Pharmacy Inc

Fievet Pharmacy Inc is a Washington, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Consumer Healthcare Products Association

Founded in 1881, the Consumer Healthcare Products Association (CHPA) is the national trade association representing the leading manufacturers and marketers of over-the-counter (OTC) medicines, dietary supplements, and consumer medical devices. Every dollar spent by consumers on OTC medicines saves the U.S. healthcare system $6-$7, contributing a total of $102 billion in savings each year. CHPA is committed to promoting the increasingly vital role of OTC medicines and dietary supplements in America`s healthcare system through science, education, and advocacy.

BCY LifeSciences

BCY LifeSciences Inc. is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Edgewise Therapeutics

Edgewise Therapeutics is a biotechnology company harnessing proven expertise and understanding of skeletal muscle physiology to develop novel, transformative therapies for serious muscle diseases. Based in Boulder, Colorado, we have built a state-of-the-art muscle research facility to capitalize on new insights into the nature and consequences of muscle adaptation and injury with disease. Edgewise recently closed it`s Series B financing round which will support the advancement of Edgewise Therapeutic`s lead product candidate into clinical development for Duchenne and Becker Muscular Dystrophy (DMD and BMD) as well as expansion of the company`s pipeline. The company`s leadership team has founded multiple biotechnology startups, several of which have gone on to become publicly-traded companies and brings to bear a depth of experience in drug discovery, development and commercialization.